XPR1 and hypertriglyceridemia: LncRNA, liver-specific triglyceride regulator, was recently identified and showed to inhibit apolipoprotein C2 (apoC2) expression through a famesoid X receptor-mediated pathway, whose depletion led to robust lipoprotein lipase activation and hypertriglyceridemia [17].